PDGFRB and neoplasm: Sorafenib is a commonly used clinical multitarget tyrosine kinase receptor inhibitor, it can inhibit VEGFR, PDGFR‐β, and RAF/MEK/ERK signaling pathways, thereby inhibiting tumor cell proliferation and blocking tumor neovascularization.210